Production (Stage)
ACADIA Pharmaceuticals Inc.
ACAD
$21.98
$0.432.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.89% | 3.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.89% | 3.67% | |||
| Cost of Revenue | -19.49% | 43.38% | |||
| Gross Profit | 6.27% | -16.90% | |||
| SG&A Expenses | -2.85% | 9.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.92% | 23.92% | |||
| Operating Income | 176.04% | -84.99% | |||
| Income Before Tax | -82.76% | 315.10% | |||
| Income Tax Expenses | -49.31% | 187.09% | |||
| Earnings from Continuing Operations | -86.79% | 338.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.79% | 338.71% | |||
| EBIT | 176.04% | -84.99% | |||
| EBITDA | 82.27% | -75.16% | |||
| EPS Basic | -86.81% | 337.23% | |||
| Normalized Basic EPS | 90.31% | -72.95% | |||
| EPS Diluted | -87.19% | 335.16% | |||
| Normalized Diluted EPS | 89.56% | -72.97% | |||
| Average Basic Shares Outstanding | 0.16% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.58% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||